Tag: MIPS
IDT announces successful manufacture of Australia’s first mRNA COVID-19 vaccine candidate
It took just five months for Victorian scientists and manufacturers to develop Australia's first mRNA COVID-19 vaccine candidate — the country's first ever mRNA medicinal product – allowing...
IDT Australia ready to begin small-scale manufacturing of Australia’s first mRNA vaccine in preparation...
Boronia-based company IDT Australia is set to take delivery of a key piece of equipment that will enable the critical manufacturing capability of mRNA...
IDT in talks to manufacture Australia’s first COVID-19 vaccine candidate
Melbourne-based pharmaceutical manufacturer IDT Australia is locked in discussions with the Victorian Government, mRNA Victoria and the Monash Institute of Pharmaceutical Sciences (MIPS) to...
Monash awarded $5m grant to manufacture Australia’s first COVID-19 vaccine candidate
The Monash Institute of Pharmaceutical Sciences (MIPS) has received $5 million from the Victorian Government to manufacture doses of Australia’s first COVID-19 vaccine candidate...
Industry partnership yields high recognition
The Monash Institute of Pharmaceutical Sciences (MIPS) has received high recognition for the Monash-GSK Australian Center for Innovation and Industrialization Project aimed at developing...
Featured Article
Navigating energy price volatility with predictive intelligence
Energy price volatility has become a structural feature of modern electricity markets rather than a temporary disruption. For energy-intensive manufacturers and large commercial operators, fluctuating wholesale prices are reshaping how energy costs are managed, making reactive approaches increasingly inadequate.
